FDA extends shelf-life for IV fluids in shortage after Hurricane Helene

In The Headlines: How tariffs could cause direct harm to patients

In this episode of the Cancer Letter Podcast, all three of The Cancer Letter’s reporters come together to talk about the potential impact of President Donald Trump’s tariffs on cancer care.

March 26, 2025

Vol.51 No.11

In Brief

UNC researchers awarded up to $10M to leverage data science

A team of UNC-Chapel Hill researchers has been awarded up to $10 million in Advanced Research Projects Agency for Health funding to develop the Cancer Identification and Precision Oncology Center (CIPOC).

December 06, 2024

Vol.50 No.45

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on schedule
Helene knocks out Baxter facility, creating shortage of IV fluids

Hurricane Milton via satellite on Wednesday. Source: NOAA/NESDISSTAR GOES-EastMilton—the second hurricane in as many weeks—ripped through America’s southeast, causing severe flooding, washing away bridges, knocking out power and water supply.

October 11, 2024

Vol.50 No.38

By Claire Marie Porter

Letter To The Editor

Tweaking the existing systems is not the answer to drug shortages

In the July 19 article “Platinum drugs are off the shortage list, but the underlying problem is unsolved,” FDA Commissioner Robert Califf and others describe a solution to the U.S. drug shortage as a matter of paying more for generic drugs.

July 26, 2024

Vol.50 No.30

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.

July 19, 2024

Vol.50 No.29

By Jacquelyn Cobb

Conversation with The Cancer Letter

Robert L. Ferris named executive director of UNC Lineberger—with an additional job as chief of oncology services

Robert L. Ferris, a head-and-neck surgeon and an expert in cancer immunotherapy was named the executive director of UNC Lineberger Comprehensive Cancer Center and the chief of oncology services at UNC Health.

June 21, 2024

Vol.50 No.25

By Paul Goldberg

FDA extends shelf-life for IV fluids in shortage after Hurricane Helene

YOU MAY BE INTERESTED IN

In The Headlines: How tariffs could cause direct harm to patients

UNC researchers awarded up to $10M to leverage data science

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on schedule
Helene knocks out Baxter facility, creating shortage of IV fluids

Tweaking the existing systems is not the answer to drug shortages

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Robert L. Ferris named executive director of UNC Lineberger—with an additional job as chief of oncology services

Renew today!

Subscriber content

FDA extends shelf-life for IV fluids in shortage after Hurricane Helene

YOU MAY BE INTERESTED IN

In The Headlines: How tariffs could cause direct harm to patients

UNC researchers awarded up to $10M to leverage data science

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on scheduleHelene knocks out Baxter facility, creating shortage of IV fluids

Tweaking the existing systems is not the answer to drug shortages

Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Robert L. Ferris named executive director of UNC Lineberger—with an additional job as chief of oncology services

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on schedule
Helene knocks out Baxter facility, creating shortage of IV fluids

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”